Surgery Partners Files 8-K

TL;DR

Surgery Partners filed an 8-K on 3/26/24, updating on corporate events and financials.

AI Summary

Surgery Partners, Inc. filed an 8-K on March 26, 2024, reporting on other events and financial statements. The filing details the company's principal executive offices located at 340 Seven Springs Way, Suite 600, Brentwood, Tennessee, 37027, with a business phone number of (615) 234-5900.

Why It Matters

This 8-K filing provides official updates and financial information from Surgery Partners, Inc., which is important for investors and stakeholders to monitor the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.

Key Players & Entities

• Surgery Partners, Inc. (company) — Registrant
• March 26, 2024 (date) — Date of Report
• 340 Seven Springs Way, Suite 600, Brentwood, Tennessee 37027 (address) — Principal Executive Offices
• 615-234-5900 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share SGRY The Nasdaq Global Select
• $800.0 million — s, relating to the issuance and sale of $800.0 million in aggregate principal amount of the Is

Filing Documents

• sgry-20240326.htm (8-K) — 23KB
• exhibit9912024notespricing.htm (EX-99.1) — 8KB
• sgrylogoa32.jpg (GRAPHIC) — 123KB
• 0001638833-24-000081.txt ( ) — 323KB
• sgry-20240326.xsd (EX-101.SCH) — 2KB
• sgry-20240326_lab.xml (EX-101.LAB) — 21KB
• sgry-20240326_pre.xml (EX-101.PRE) — 12KB
• sgry-20240326_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On March 26, 2024, Surgery Center Holdings, Inc. (the "Issuer"), entered into a purchase agreement with Barclays Capital Inc. as representative of certain initial purchasers, relating to the issuance and sale of $800.0 million in aggregate principal amount of the Issuer's 7.250% senior unsecured notes due 2032 (the "Notes Offering"). The net proceeds from the Notes Offering, will be used to redeem all of the Issuer's outstanding 6.750% senior unsecured notes due July 1, 2025 (the "2025 Notes") and outstanding 10.000% senior unsecured notes due April 15, 2027 (the "2027 Notes"), to pay the accrued and unpaid interest on the 2025 Notes and 2027 Notes to, but not including, the date of redemption and to pay related fees and expenses in connection with the offering and the redemption of the 2025 Notes and 2027 Notes. The excess proceeds from the Notes Offering will be used for general corporate purposes, including to fund future acquisitions. The consummation of the Notes Offering is subject to market and other conditions. On March 26, 2024, Surgery Partners, Inc. issued a press release announcing the pricing of the notes offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits: 99.1 Press release dated March 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SURGERY PARTNERS, INC. By: /s/ David T. Doherty David T. Doherty Executive Vice President and Chief Financial Officer Date: March 26, 2024

View Full Filing

View this 8-K filing on SEC EDGAR